Compare VPG & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | RZLT |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.7M | 352.1M |
| IPO Year | 2010 | 2011 |
| Metric | VPG | RZLT |
|---|---|---|
| Price | $48.90 | $4.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $74.33 | $10.80 |
| AVG Volume (30 Days) | 296.1K | ★ 1.5M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,202,000.00 | N/A |
| Revenue This Year | $12.08 | N/A |
| Revenue Next Year | $7.69 | $2,410.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $29.14 | $1.07 |
| 52 Week High | $151.78 | $11.17 |
| Indicator | VPG | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 52.90 |
| Support Level | $41.35 | $3.58 |
| Resistance Level | $61.50 | $4.22 |
| Average True Range (ATR) | 3.77 | 0.39 |
| MACD | 0.43 | 0.04 |
| Stochastic Oscillator | 52.75 | 60.24 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.